JZL-195

JZL-195 is a small-molecule, dual inhibitor of both fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the two main enzymes responsible for the degradation of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. By inhibiting these enzymes, JZL-195 raises brain levels of both AEA and 2-AG, thereby enhancing endocannabinoid signaling. The compound has been shown in animal studies to produce cannabinoid-like behavioral responses, including anti-allodynic effects greater than selective FAAH or MAGL inhibitors alone, suggesting greater potential for alleviating neuropathic and inflammatory pain. JZL-195 is primarily utilized as a research tool to study the endocannabinoid system and its modulation in vivo[1][4][6][7][9][10].

Other names

4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate4-Nitrophenyl 4-[(3-phenoxyphenyl)methyl]-1-piperazinecarboxylate4-[(3-Phenoxyphenyl)methyl]-1-piperazinecarboxylic acid 4-nitrophenyl ester1-Piperazinecarboxylic acid, 4-[(3-phenoxyphenyl)methyl]-, 4-nitrophenyl esterJZL195 hydrochlorideJZL-195 hydrochlorideJZL 195 hydrochlorideFAAH/MAGL inhibitor